AUSTIN, TX, July 14, 2022 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it has been selected to participate in UnitedHealthcare’s Preferred Laboratory Network (PLN). Adding Natera to the network was effective July 1, 2022.

UnitedHealthcare’s PLN is comprised of laboratory care providers who have met the insurer’s highest standards for access, cost, data, quality and service, based on a process of application and rigorous review. UnitedHealthcare is working with these labs to continue its efforts to improve the experience for healthcare providers and members.

UnitedHealthcare describes PLN as “an advanced way to work with select laboratory providers to deliver care that places greater emphasis on patient outcomes and the total cost of a person’s care.”

“Natera is thrilled to be a part of UnitedHealthcare’s PLN and we look forward to continuing to provide UHC plan members with an exceptional experience,” said Matthew Mega, Vice President, Market Access at Natera. “We remain committed to integrating personalized genetic testing and diagnostics into the standard of care.”

Since its inception, Natera has performed more than 3 million cfDNA tests worldwide, helping patients and their providers make critical healthcare decisions in oncology, women’s health and organ health.

UnitedHealthcare offers the full range of health benefit programs for individuals, employers, and Medicare and Medicaid beneficiaries, and contracts directly with more than 1.5 million physicians and healthcare professionals, and 7,000 hospitals and other healthcare facilities across the country.

About Natera

Natera™ is a global leader in cell-free DNA testing, dedicated to oncology, women’s health and organ health. Our goal is to integrate personalized genetic testing and diagnostics into the standard of care to protect health and inform earlier, more targeted interventions that help lead longer, healthier lives. Natera’s tests are validated by over 100 peer-reviewed publications that demonstrate high accuracy. Natera operates laboratories that are ISO 13485 certified and CAP accredited under the Clinical Laboratory Improvement Amendments (CLIA) in Austin, TX and San Carlos, California. For more information, visit www.natera.com.

Forward-looking statements

All statements other than statements of historical facts contained in this press release are forward-looking statements and do not constitute a representation that Natera’s plans, estimates or expectations will be achieved. These forward-looking statements represent Natera’s expectations as of the date of this press release, and Natera disclaims any obligation to update any forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially, including with respect to our efforts to develop and market new product offerings, and our ability to grow our business. Additional risks and uncertainties are discussed in more detail in the “Risk Factors” section of Natera’s recent filings on Forms 10-K and 10-Q and in other filings by Natera with the SEC from time to time. other. These documents are available at www.natera.com/investors and www.sec.gov.

contacts
Investor Relations: Mike Brophy, Chief Financial Officer, Natera, Inc., 510-826-2350
Media: Kate Stabrawa, Communications, Natera, Inc., 720-318-4080 [email protected]

SOURCENatera, Inc.